

**BME - GROWTH**  
Palacio de la Bolsa  
Plaza de la Lealtad, 1  
28014 Madrid

Alicante, 23rd of August 2024

**COMMUNICATION- PRIVILEGED INFORMATION- FACEPHI BIOMETRIA, S.A.**

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the Law 6/2023 17<sup>th</sup> March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter “FacePhi” or “the Company”, interchangeably).

On August 21, 2024, Facephi and Nice & Green, the Company's main shareholder, have signed a capitalizable loan amounting 1,800,000 euros, of which 300,000 euros have been drawn down as of the date of the agreement.

The terms of the loan are as follows:

- The maturity date of the loan is three (3) months from the signature´s date.
- Parties may agree on or prior to the maturity date to capitalize the loan (by means of a “credit offset”). In such agreement the parties would determine the exchange rate of the shares to be issued.
- The loan will accrue interest at Euribor plus 2%.
- The loan has a formalization fee of 7%.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

---

Javier Mira Miró  
**Chairman of the Board of Directors**